New diphenylacetylenes as probes for positron emission tomographic imaging of amyloid plaques

被引:28
作者
Chandra, Rajesh
Oya, Shunichi
Kung, Mei-Ping
Hou, Catherine
Jin, Lee-Way
Kung, Hank F.
机构
[1] Univ Penn, Dept Radiol, Philadelphia, PA 19104 USA
[2] Univ Penn, Dept Pharmacol, Philadelphia, PA 19104 USA
[3] Univ Calif Davis, Hlth Syst, Dept Pathol, Sacramento, CA 95817 USA
关键词
D O I
10.1021/jm070090j
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
A series of F-18 fluoropegylated diphenylacetylenes as probes for binding to A beta plaques were successfully prepared. These relatively rigid acetylenes, 12a, 12b, 14a, and 14b, displayed high binding affinities in postmortem AD brain homogenates (K-i ranging from 1.2 to 2.9 nM). In vivo biodistribution in normal mice exhibited excellent initial brain penetrations (4.42, 4.55, 5.41, and 6.78% dose/g at 2 min for [F-18]12a, 12b, 14a, and 14b, respectively). [F-18]12b and [F-18]14b, with a longer fluoropegylated unit, that is, n = 3, showed faster brain washout at 30 min postinjection (0.42 and 1.57% dose/g) as compared to the shorter fluoropegylated chain ligands, that is, [F-18]12a and [F-18]14a(1.03 and 3.69% dose/g). Autoradiography and homogenate binding confirmed the high binding signal due to A beta plaques. These preliminary results suggest that the novel diphenylacetylenes may be potentially useful for imaging of A beta plaques in the brain of patients with Alzheimer's disease.
引用
收藏
页码:2415 / 2423
页数:9
相关论文
共 35 条
[11]   Technology Insight: imaging amyloid plaques in the living brain with positron emission tomography and MRI [J].
Huddleston, DE ;
Small, SA .
NATURE CLINICAL PRACTICE NEUROLOGY, 2005, 1 (02) :96-105
[12]   Serotonin 1A receptors in the living brain of Alzheimer's disease patients [J].
Kepe, V ;
Barrio, JR ;
Huang, SC ;
Ercoli, L ;
Siddarth, P ;
Shoghi-Jadid, K ;
Cole, GM ;
Satyamurthy, N ;
Cummings, JL ;
Small, GW ;
Phelps, ME .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2006, 103 (03) :702-707
[13]   Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B [J].
Klunk, WE ;
Engler, H ;
Nordberg, A ;
Wang, YM ;
Blomqvist, G ;
Holt, DP ;
Bergström, M ;
Savitcheva, I ;
Huang, GF ;
Estrada, S ;
Ausén, B ;
Debnath, ML ;
Barletta, J ;
Price, JC ;
Sandell, J ;
Lopresti, BJ ;
Wall, A ;
Koivisto, P ;
Antoni, G ;
Mathis, CA ;
Långström, B .
ANNALS OF NEUROLOGY, 2004, 55 (03) :306-319
[14]   Binding of two potential imaging agents targeting amyloid plaques in postmortem brain tissues of patients with Alzheimer's disease [J].
Kung, MP ;
Hou, C ;
Zhuang, ZP ;
Skovronsky, D ;
Kung, HF .
BRAIN RESEARCH, 2004, 1025 (1-2) :98-105
[15]   Characterization of IMPY as a potential imaging agent for β-amyloid plaques in double transgenic PSAPP mice [J].
Kung, MP ;
Hou, C ;
Zhuang, ZP ;
Cross, AJ ;
Maier, DL ;
Kung, HF .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2004, 31 (08) :1136-1145
[16]   Imaging β-amyloid plaques and neurofibrillary tangles in the aging human brain [J].
Mathis, CA ;
Wang, Y ;
Klunk, WE .
CURRENT PHARMACEUTICAL DESIGN, 2004, 10 (13) :1469-1492
[17]  
Mathis CA, 2002, J NUCL MED, V43, p166P
[18]  
MOHAMED AMS, 2004, TETRAHEDRON, V60, P9977
[19]  
Newberg AB, 2006, J NUCL MED, V47, P748
[20]   Imaging and in vivo quantitation of β-amyloid:: An exemplary biomarker for Alzheimer's disease? [J].
Nichols, Lisa ;
Pike, Victor W. ;
Cai, Lisheng ;
Innis, Robert B. .
BIOLOGICAL PSYCHIATRY, 2006, 59 (10) :940-947